标题
HER2 expression in urothelial carcinoma, a systematic literature review
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-10-21
DOI
10.3389/fonc.2022.1011885
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).
- (2022) Michael Lattanzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.
- (2022) Siming Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis
- (2022) Alberto Martini et al. CANCER TREATMENT REVIEWS
- The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
- (2022) Giorgio Patelli et al. CANCER TREATMENT REVIEWS
- Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.
- (2022) Huizi Lei et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer
- (2021) Gillian Vandekerkhove et al. Nature Communications
- Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar immune microenvironment as compared to conventional UC.
- (2021) Myriam Kossai et al. JOURNAL OF CLINICAL ONCOLOGY
- 711P Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
- (2021) C.J. Pobel et al. ANNALS OF ONCOLOGY
- Histological Variants of Urothelial Carcinoma Predict No Response to Neoadjuvant Chemotherapy
- (2021) Katia Ramos Moreira Leite et al. Clinical Genitourinary Cancer
- RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.
- (2021) Li Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis
- (2021) Kai Gan et al. Frontiers in Oncology
- Comprehensive genomic profiling of histologic subtypes of urethral carcinomas
- (2021) Joseph Jacob et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions
- (2020) Russell W. Madison et al. BJU INTERNATIONAL
- Novel HER2‐targeted therapies for HER2‐positive metastatic breast cancer
- (2020) Siddharth Kunte et al. CANCER
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma
- (2020) M.L. Abel et al. Clinical Genitourinary Cancer
- Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity
- (2020) Claud M. Grigg et al. HUMAN PATHOLOGY
- Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes
- (2020) Omar Alhalabi et al. MOLECULAR CANCER RESEARCH
- Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis
- (2020) Zsolt Hepp et al. Journal of Managed Care & Specialty Pharmacy
- HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
- (2019) Gustavo Baretton et al. VIRCHOWS ARCHIV
- Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma.
- (2019) Nima Almassi et al. JOURNAL OF CLINICAL ONCOLOGY
- Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC).
- (2019) Dario Martin Villamar et al. JOURNAL OF CLINICAL ONCOLOGY
- PD47-03 CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER
- (2019) Nima Almassi* et al. JOURNAL OF UROLOGY
- Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
- (2019) Edith A. Perez et al. CANCER
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
- (2019) Brian D. Robinson et al. Nature Communications
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer
- (2019) Yun Chiang et al. Journal of Clinical Medicine
- Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
- (2018) Neeraj Agarwal et al. CANCER
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility
- (2018) Anissa Moktefi et al. MODERN PATHOLOGY
- Update on the Treatment of Metastatic Urothelial Carcinoma
- (2018) Nedal Bukhari et al. TheScientificWorldJOURNAL
- Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
- (2018) Luc Cabel et al. Oncotarget
- Update on the Treatment of Metastatic Urothelial Carcinoma
- (2018) Nedal Bukhari et al. Scientific World Journal
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
- (2018) Thomas W. Flaig et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
- (2017) Pontus Eriksson et al. Oncotarget
- Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
- (2017) Bernhard Kiss et al. Scientific Reports
- HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
- (2016) Angela N. Bartley et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
- (2016) Taoufik Nedjadi et al. BMC CANCER
- Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases
- (2016) Abigail L. Goodman et al. HUMAN PATHOLOGY
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
- (2016) Noura J. Choudhury et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer
- (2016) Francesco Soria et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)
- (2016) Francesco Soria et al. WORLD JOURNAL OF UROLOGY
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
- (2015) Jeffrey S. Ross et al. CANCER
- Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy
- (2015) Andrea Necchi et al. Clinical Genitourinary Cancer
- Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin
- (2015) Sherri Z. Millis et al. Clinical Genitourinary Cancer
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
- (2015) Stéphane Oudard et al. EUROPEAN JOURNAL OF CANCER
- Urinary tract cancer survival in Europe 1999–2007: Results of the population-based study EUROCARE-5
- (2015) Rafael Marcos-Gragera et al. EUROPEAN JOURNAL OF CANCER
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 as a target in invasive urothelial carcinoma
- (2015) Joaquim Bellmunt et al. Cancer Medicine
- Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis
- (2014) Junjie Zhao et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy
- (2013) Jeffrey S Ross et al. MODERN PATHOLOGY
- Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study
- (2012) Michael Rink et al. EUROPEAN UROLOGY
- A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens
- (2012) Donna E. Hansel et al. EUROPEAN UROLOGY
- Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression
- (2012) Paul Chih-Hsueh Chen et al. JOURNAL OF CLINICAL PATHOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Therapeutic Challenges in Advanced Bladder Cancer
- (2012) Joaquim Bellmunt et al. SEMINARS IN ONCOLOGY
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
- (2011) Achim Fleischmann et al. EUROPEAN UROLOGY
- Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder
- (2010) Christian Bolenz et al. BJU INTERNATIONAL
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder
- (2010) Yamada ONCOLOGY REPORTS
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
- (2009) M. Lae et al. ANNALS OF ONCOLOGY
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- HER2Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated WithMYCCoamplification in a Subset of Cases
- (2008) Donna E. Hansel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started